INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING

INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING

To inhibit tyrosine kinase 2 mediated signaling.SOLUTION: Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salts thereof, where R, R, R, R, R, X, X, X, X, Xand n are as defined herein, pharmaceutical compositions comprising the same, and methods of preparation and use.SE...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MARIA A ARGIRIADI, ELLEN YULIN TSAI CHIEN, LIU HUAQING, STACY A VAN EPPS, MICHAEL M FRIEDMAN, MATTHEW P WEBSTER, DAVID A SCHIEDLER, J MARTIN HEROLD, ANDREW J LITTLE, MICHAEL R SCHRIMPF, DAVID J HARDEE, MARLON D COWART, THOMAS R VARGO, MATTHEW H KATCHER, MARC J SCANIO, KRISTINE E FRANK, THERESA A DUNSTAN, ERIC C BREINLINGER, WEI QIU
Format: Patent
Sprache:eng ; jpn
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To inhibit tyrosine kinase 2 mediated signaling.SOLUTION: Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salts thereof, where R, R, R, R, R, X, X, X, X, Xand n are as defined herein, pharmaceutical compositions comprising the same, and methods of preparation and use.SELECTED DRAWING: Figure 1 【課題】チロシンキナーゼ２媒介性シグナル伝達を阻害すること。【解決手段】式（Ｉ）の化合物及びその薬学的に許容される塩（式中、Ｒ１、Ｒ２、Ｒ３、Ｒ４ａ、Ｒ４ｂ、Ｘ１、Ｘ２、Ｘ３、Ｘ４、Ｘ５及びｎは、本明細書で定義した通りである）、それを含む医薬組成物、並びに調製方法及び使用方法が、本明細書において開示されている。【選択図】図１